Covishield Blood Clot Risk Minuscule but Govt Not Transparent: Gagandeep Kang

An illustration of Dr Gagandeep Kang with vaccine vials within the background. Images: Twitter and Reuters

India’s high vaccine scientist professor Gagandeep Kang says if European ranges of threat of blood clots from AstraZeneca’s COVID-19 vaccine candidate – 1 out of 100,000 as per the European Medicines Company and 1 out of 250,000 as per the British Well being Regulator – have been to use to India, we’d have a complete of three,000 circumstances out of our complete goal of 300 million folks to be vaccinated. Put otherwise, this implies out of the 80 million vaccines already given we must always have 320 circumstances. This, Kang, says is a “very small threat” and there’s completely no want for apprehension.

In a 35-minute interview to Karan Thapar for The Wire, Kang, who is taken into account India’s high vaccine scientist, did add that within the nation, we merely would not have any official info whether or not there have been worrying blood clots with a low platelet depend after taking a dose of the Covishield vaccine, the title below which AstraZeneca’s vaccine candidate is being bought in India.

Kang stated it’s blood clots in veins within the mind and the stomach, accompanied by low platelet depend, that we have to look out for. She had little question that hospitals would have this info, however she didn’t know if it has reached the federal government’s hostile occasions committee or, if it has, what it has carried out with the information. The committee and the federal government have merely not stated something in any respect. There isn’t a transparency in any respect concerning this matter, Kang stated. Later within the interview, she stated the federal government “is attempting to do its finest.”

Kang advised The Wire that it’s not potential that India has given 80 million doses of Covishield however had no circumstances of blood clotting in any respect. There are sure to be a number of or a number of circumstances of people that have had blood clots after getting a jab. That’s to be anticipated. What we have to know is whether or not these blood clots have been accompanied by a low platelet depend.



Kang stated the federal government should expeditiously arrange an inquiry which should look into this matter in a time sure method and make its report absolutely public. Such a committee should embrace scientific haematologists, specialists in vaccinology and epidemiologists. She additionally cited the instance of the small print and full transparency set by Britain’s well being regulator as one the Indian system should emulate.

Nonetheless, Kang added until this committee experiences, there isn’t a want for India to comply with the British and European instance and resolve to not give Covishield to explicit age teams. She stated there’s completely little question the advantages of Covishield far outweigh the very small dangers.

Kang stated it’s extremely unlikely India will cease giving Covishield to any age group. Nonetheless she added that if it does, provide of vaccines for India’s vaccination programme will likely be an enormous constraint. We merely don’t make sufficient Covaxin to exchange Covishield. On this context, Kang additionally stated India should expeditiously clear different vaccines like Sputnik and people developed by Johnson and Johnson and Novavax, the primary two of that are already getting used internationally.

Lastly, on the finish of the interview, Kang spelt out in appreciable element the signs individuals who’ve had Covishield ought to look out for if they’re apprehensive of creating blood clots.

Scroll to Top